Hallucinogens, stimulants, and related drugs of abuse and their therapeutic potential

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2013, Pages 632-657

  Glennon, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877715250     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Nichols D. Legal highs: the dark side of medicinal chemistry. Nature 2011;469:7.
2. Brimblecombe RW, Pinder RM. Hallucinogenic Agents. Bristol, UK: Wright- Scientechnica, 1975.
3. Hollister LE. Chemical Psychoses. Springfield, IL: Charles C. Thomas, 1968.
4. Glennon RA. Animal models for assessing hallucinogenic agents. In: Boulton AA, Baker GB, Wu PH, eds. Animal Models of Drug Addiction. Totowa, NJ: Humana Press, 1992:345-381.
5. Glennon RA, Young R, eds, Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies, Hoboken, NJ; John Wiley and Sons, 2011.
6. Glennon RA. Discriminative stimulus properties of hallucinogens and related designer drugs. In: Glennon RA, Jarbe TUC, Frankenheim J, eds. Drug Discrimination: Applications to Drug Abuse Research. Rockville, MD: National Institute on Drug Abuse, 1991:25-44.
7. Lin JC, Glennon RA, eds. Hallucinogens: An Update. Rockville, MD: National Institute on Drug Abuse, 1994.
8. Padgett LW. Recent developments in cannabinoid ligands. Life Sci 2005;77:1767-1798.
9. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147:S163-S171.
10. Reggio PH, ed. The Cannabinoid Receptors. Berlin: Springer, 2009.
11. Hanus L, Gopher A, Almog S, et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993;36:3032-3034.
12. Jarbe TUC, Lamb RL, Makriyannis A, et al. (R)-methanandamide as a discriminative stimulus in rats: tests with anandamide and D9-THC. Behav Pharmacol 1998;9:S47.
13. Mackie K. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol 2006;46:101-123.
14. Martin BR. Marijuana. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995:1757-1765.
15. Huffman JW. CB2 receptor ligands. Mini Rev Med Chem 2005;5:641-649.
16. Corey S. Recent development in the therapeutic potential of cannabinoids. P R Health Sci J 2005;24:19-26.
17. Prem S. Overview of phencyclidine (PCP) intoxication in children and adolescents. UpToDate, http://www.uptodate.com/patients/content/topic. do?topicKey=~G5GcywxXRlFVI, 2010.
18. Bey T, Patel A. Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. West J Emerg Med 2007;8:9-14.
19. Balster RL, Willetts J. Phencyclidine: a drug of abuse and a tool for neuroscience research. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology Series, Vol 118. Berlin: Springer, 1996:233-262.
20. Glennon RA. Pharmacophore identification for sigma-1(s1) receptor binding- application of the "deconstruction-reconstruction-elaboration" approach. Mini Rev Med Chem 2005;5:927-940.
21. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 2005;5:101-106.
22. Balster RL. Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In: Glennon RA, Jarbe TUC, Frankenheim J, eds. Drug Discrimination: Applications to Drug Abuse Research. Rockville, MD: National Institute on Drug Abuse, 1991:163-180.
23. Shulgin AT, Shulgin A. Tihkal. Berkeley, CA: Transform Press, 1997.
24. Murphree HB, Dippy RH, Jenney EH, et al. Effects in normal man of a-methyltryptamine and a-ethyltryptamine. Clin Pharmacol Ther 1961;2:722-726.
25. Siva Sankar DV, ed. LSD: a total study. Westbury, NY: PJD Publications, 1975.
26. Pfaff RC, Huang X, Marona-Lewicka D, et al. Lysergamides revisited. In: Lin JC, Glennon RA, eds. Hallucinogens: an update. Rockville, MD: National Institute on Drug Abuse, 1994:52-73.
27. Naranjo C. Psychotropic properties of harmala alkaloids. In: Efron DK, Holmstedt B, Kline NS, eds. Ethnopharmacologic search for psychoactive drugs. Washington, DC: U.S. Government Printing Office, 1967:385-391.
28. Naranjo C. The Healing Journey. New York: Pantheon Books, 1973.
29. Grella B, Dukat M, Young R, et al. Investigation of hallucinogenic and related b-carbolines. Drug Alcohol Depend 1998;50:99-107.
30. Shulgin AT, Shulgin A. Pihkal. Berkeley, CA: Transform Press, 1991.
31. Glennon RA. Classical hallucinogens. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology Series, Vol 118. Berlin: Springer, 1996:343-371.
32. Nelson DL, Lucaites VL, Wainscot DB, et al. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B, and 5-HT2C receptors. Naunyn-Schmeideberg's Arch Pharmacol 1998;359:1-6.
33. Griffiths RR, Mumford GK. Caffeine reinforcement, discrimination, tolerance, and physical dependence in laboratory animals and humans. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology Series, Vol 118. Berlin: Springer, 1996:315-341.
34. Daly JW. Caffeine analogs: biomedical impact. Cell Mol Life Sci 2007;64:2153-2169.
35. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2007;109:671-680.
36. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002;99:8921-8926.
37. Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-818.
38. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004;61:857-872.
39. Sahin B, Galdi S, Hendrick T, et al. Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling. Brain Res 2007;1129:1-14.
40. Cho AK, Segal DS, eds. Amphetamine and Its Analogues. San Diego: Academic Press, 1994:43-77.
41. Young R, Glennon RA. Discriminative stimulus properties of amphetamine and structurally related phenalkylamines. Med Res Rev 1986;6:99-130.
42. Young R, Gabryszuk M, Glennon RA. (-)-Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects. Pharmacol Biochem Behav 1998;61:169-173.
43. Cho AK, Kumagai Y. Metabolism of amphetamine and other arylisopropylamines. In: Cho AK, Segal DS, eds. Amphetamine and Its Analogues. San Diego: Academic Press, 1994:43-77.
44. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 2002;16:717-742.
45. Linne Y, Rossner S. Pharmacotherapy of obesity. Clin Dermatol 2004;22:319-324.
46. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841.
47. Setola V, Dukat M, Glennon RA, et al. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005;68:20-33.
48. van Gaal L, Mertens I, Ballaux D, et al. Modern, new pharmacotherapy for obesity. Best Pract Res Clin Endocrinol Metab 2004;18:1049-1072.
49. Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 2004;8:339-354.
50. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27:1181-1194.
51. Black J, Guilleminault C. Medications for the treatment of narcolepsy. Expert Opin Emerg Drugs 2001;6:239-247.
52. Schwartz JR. Modafinil: new indications for wake promotion. Expert Opin Pharmacother 2005;6:115-129.
53. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 2004;8:355-366.
54. Mignot E. An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy. Sleep Med Rev 2004;8:333-338.
55. Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in the behavioral stimulant effects of modafinil. J Pharm Exp Ther 2009;329:738-746.
56. Seeman P, Guan H-C, Hirbec H. Dopamine D2 receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009;63:698-704.
57. Fischman MW, Johanson CE. Cocaine. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology Series, Vol 118. Berlin: Springer, 1996:159-195.
58. Carroll FI, Lewin AH, Boja JW, et al. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 1992;35:969-981.
59. Newman AH. Novel dopamine transporter ligands: the state of the art. Med Chem Res 1998;8:1-11.
60. Deutsch HM, Shi Q, Gruszecka-Kowalik E, et al. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogues. J Med Chem 1996;39:1201-1209.
61. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine abuse. CNS Drugs 2005;19:13-25.
62. Singh S. Chemistry, design, and structure-activity relationships of cocaine antagonists. Chem Rev 2000;100:925-1024.
63. Heal DJ, Pierce DM. Methylphenidate and it isomers. CNS Drugs 2006;20:713-738.
64. Froimowitz M, Patrick KS, Cody V. Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT. Pharmaceut Res 1995;12:1430-1434.
65. Srinivas NR, Hubbard JW, Korchinski ED, et al. Enantioselective pharmacokinetics of dl-threo-methylphenidate. Pharmaceut Res 1993;10:14-21.
66. Khorana N, Pullagurla M, Dukat M, et al. Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol Biochem Behav 2004;78:821-826.
67. Glennon RA, Young R, Jacyno JM, et al. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 1983;86:453-459.
68. Nichols DE, Oberlender R. Structure-activity relationships of MDMA-like substances. In: Ashgar K, De Souza E, eds. Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. Washington, DC: U.S. Government Printing Office, 1989:1-29.
69. Oberlender R, Nichols DE. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2- butanamine as a discriminative stimulus in studies of 3,4-methylenedioxyamphetamine- like behavioral activity. J Pharmacol Exp Ther 1990;255:1098-1106.
70. Glennon RA, Young R, Dukat M, et al. Initial characterization of PMMA as a discriminative stimulus. Pharmacol Biochem Behav 1997;57:151-158.
71. Glennon RA. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 1999;64:251-256.
72. Wax PM. Just a click away: recreational drug web sites on the internet. Pediatrics 2002;109:96-100.
73. Benavides DR, Bibb JA. Role of Cdk5 in drug abuse and plasticity. Ann N Y Acad Sci 2004;1025:335-344.
74. Svenningsson P, Tzavara ET, Liu F, et al. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci U S A 2002;99:3188-3193.
75. Svenningsson P, Tzavara ET, Carruthers R, et al. Diverse psychotomimetics act through a common signaling pathway. Science 2003;302:1412-1415.
76. Svenningsson P, Nishi A, Fisone G, et al. DARPP-32: an integrator of neurotransmission. Ann Rev Pharmacol Toxicol 2004;44:269-296.
77. Nairn AC, Svenningsson P, Nishi A, et al. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2004;47(Suppl 1):14-23.
78. Gould TD, Manji HK. DARPP-32: a molecular switch at the nexus of reward pathway plasticity. Proc Natl Acad Sci U S A 2005;102:253-254.